- $242.65bn
- $269.19bn
- $45.81bn
- 93
- 25
- 89
- 78
REG - AstraZeneca PLC - Tagrisso plus chemo approved in US for lung cancer
AnnouncementREG - AstraZeneca PLC - Tagrisso improved PFS in Stage III lung cancer
AnnouncementREG - AstraZeneca PLC - Final Results
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - AstraZeneca acquires Gracell
AnnouncementREG - AstraZeneca PLC - Wainua (eplontersen) granted first US FDA approval
AnnouncementREG - AstraZeneca PLC - Director/PDMR Shareholding
AnnouncementREG - AstraZeneca PLC - AstraZeneca to acquire Icosavax
AnnouncementREG - AstraZeneca PLC - Block listing Interim Review
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - Discontinuation of two CRYSTALIZE evidence trials
AnnouncementREG - AstraZeneca PLC - Director/PDMR Shareholding
AnnouncementREG - AstraZeneca PLC - Truqap approved in US for HR+ breast cancer
AnnouncementREG - AstraZeneca PLC - Update on PACIFIC-2 Phase III trial for Imfinzi
AnnouncementREG - AstraZeneca PLC - Director Declaration
AnnouncementREG - AstraZeneca PLC - 9M and Q3 2023 results
AnnouncementREG - AstraZeneca PLC - Agreement with Eccogene for clinical stage GLP-1RA
AnnouncementREG - AstraZeneca PLC - Imfinzi combination improves PFS in liver cancer
Announcement